Prevalence of Infertility and Use of Fertility Treatment in Women with Polycystic Ovary Syndrome: Data from a Large Community-Based Cohort Study
Publication: Journal of Women's Health
Volume 24, Issue Number 4
Abstract
Background: Polycystic ovary syndrome (PCOS) affects 6%–21% of women. PCOS is the primary cause of anovulatory infertility, with major health and economic costs, yet we are unaware of any community-based, natural history studies on fertility and fertility treatments published to date. We aim to compare infertility, fertility treatment use, and relationship to body mass index (BMI) in women reporting PCOS to women not reporting PCOS in a community-based population.
Methods: This is a cross-sectional analysis of a longitudinal cohort study, the Australian Longitudinal Study on Women's Health (ALSWH). For the ALSWH, women from the general community were randomly selected from the national public insurance database. Mailed survey data were collected at multiple time points. At survey 4, there were 9145 respondents aged 28–33 years. Of 8612 women with known PCOS status, 478 women reported having PCOS. Information regarding fertility status was available for 4856 women. This was the subgroup used in this analysis. The main outcomes measures are self-reported PCOS status, BMI, infertility, and use of fertility therapies including ovulation induction and in vitro fertilization (IVF). Logistic regression was used to examine factors associated with infertility and use of fertility treatment.
Results: Self-reported PCOS prevalence was 5.8% (95% confidence interval [CI]: 5.3%–6.4%). Infertility was noted by 72% of 309 women reporting PCOS, compared with 16% of 4547 women not reporting PCOS (p<0.001). Infertility was 15-fold higher in women reporting PCOS (adjusted odds ratio 14.9, 95% CI 10.9–20.3), independent of BMI. Of women reporting infertility, there was greater use of fertility hormone treatment, (62%, n=116 vs. 33%, n=162, p<0.001) in women reporting PCOS; however, IVF use was similar.
Conclusions: In this community-based cohort of women, infertility and use of fertility hormone treatment was significantly higher in women reporting PCOS. Considering the prevalence of PCOS and the health and economic burden of infertility, strategies to optimize fertility are important.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51.
2.
Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.
3.
Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–3515.
4.
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–4011.
5.
Boyle JA, Cunningham J, O'Dea K, Dunbar T, Norman RJ. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust 2012;196:62–66.
6.
Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine 2010;8:41.
7.
Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006;12:324–332.
8.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
9.
Azziz R, Carmina E, Dewailly D, et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237–4245.
10.
Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:273–279.
11.
Meyer C, McGrath B, Cameron J, Teede H. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4630–4635.
12.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes 2002;26:883–896.
13.
Teede HJ, Joham AE, Paul E, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: Results of an observational study in young women. Obesity 2013;21:1526–1532.
14.
Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update 2012;18:618–37.
15.
Ramanand SJ, Ghongane BB, Ramanand JB, et al. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocr Metab 2013;17:138–145.
16.
Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006;113:1148–1159.
17.
Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067–3073.
18.
Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107–2111.
19.
Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: An analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32:213–220.
20.
Zaadstra BM, Seidell JC, Van Noord PA, et al. Fat and female fecundity: Prospective study of effect of body fat distribution on conception rates. BMJ 1993;306:484–487.
21.
van der Steeg JW, Steures P, Eijkemans MJ, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod 2008;23:324–328.
22.
Kumbak B, Oral E, Bukulmez O. Female obesity and assisted reproductive technologies. Semin Reprod Med 2012;30:507–516.
23.
Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007;14:482–487.
24.
Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study. Hum Fertil (Camb) 2000;3:101–105.
25.
Roos N, Kieler H, Sahlin L, et al. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ 2011;343:d6309.
26.
Lee C. Women's Health Australia: Progress on the Australian Longitudinal Study on Women's Health 1995–2000. Brisbane: Australian Academic Press Pty Ltd., 2001.
27.
Lee C, Dobson AJ, Brown WJ, et al. Cohort profile: The Australian Longitudinal Study on Women's Health. Int J Epidemiol 2005;34:987–991.
28.
Powers J, Loxton D. The impact of attrition in an 11-year prospective longitudinal study of younger women. Ann Epidemiol 2010;20:318–321.
29.
Brown WJ, Bryson L, Byles JE, et al. Women's Health Australia: Recruitment for a national longitudinal cohort study. Women Health 1998;28:23–40.
30.
World Health Organization (WHO). Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization, 1998.
31.
Hudecova M, Holte J, Olovsson M, Sundstrom Poromaa I. Long-term follow-up of patients with polycystic ovary syndrome: Reproductive outcome and ovarian reserve. Hum Reprod 2009;24:1176–1183.
32.
Hull MG. Epidemiology of infertility and polycystic ovarian disease: Endocrinological and demographic studies. Gynecol Endocrinol 1987;1:235–245.
33.
Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90:4650–4658.
34.
Wang Y, Macaldowie A, Hayward I, Chambers G, Sullivan E. Assisted reproductive technology in Australia and New Zealand 2009. Canberra: Australian Institute of Health and Welfare (AIHW), 2011.
35.
Bablok L, Dziadecki W, Szymusik I, et al. Patterns of infertility in Poland - multicenter study. Neuro Endocrinol Lett 2011;32:799–804.
36.
Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013;28:777–784.
37.
Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: A position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009;92:1966–1982.
38.
Teede H, Misso M, Deeks A, et al. Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline. Med J Aust 2011;195:S65–S112.
39.
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). College statement: Ovarian stimulation in infertility. (C-Gyn 02). Melbourne: RANZCOG, 2008.
Information & Authors
Information
Published In

Copyright
Copyright 2015, Mary Ann Liebert, Inc.
History
Published online: 10 April 2015
Published in print: April 2015
Published ahead of print: 5 February 2015
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.